{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG|Designated|Treatment of multiple myeloma" in comments (approximate match)
Status:
Investigational
Source:
NCT04278924: Phase 2 Interventional Completed Primary Immune Thrombocytopenia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:ispectamab debotansine [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:linvoseltamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02514239: Phase 1 Interventional Completed Multiple Myeloma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03362060: Phase 1 Interventional Active, not recruiting Triple Negative Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03362060: Phase 1 Interventional Active, not recruiting Triple Negative Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03362060: Phase 1 Interventional Active, not recruiting Triple Negative Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03362060: Phase 1 Interventional Active, not recruiting Triple Negative Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00278174: Phase 2 Interventional Completed Kidney Cancer
(2005)
Source URL:
Class:
PROTEIN